natgillin/translations-raw huggingface dataset:
a light chain variable region of SEQ ID NO: 15. An isolated antigen binding protein of claim 1, 2, or 3 wherein said antigen binding protein has at least one property selected from the group consisting of: 
Protein koji veže antigen iz bilo kojeg od patentnih zahtjeva 1-5, pri čemu navedeni protein koji veže antigen ima najmanje jedno svojstvo odabrano iz grupe koja se sastoji od: a) < smanjivanja aktivnosti ljudskog IL-23 u određivanju metodom STAT-luciferaze; b) smanjivanje stvaranja proupalnih citokina;
The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the pharmaceutical composition of claim 4, for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj sukladno zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak sukladno zahtjevu 4 naznačen time da je za uporabu u postupku za liječenje, upravljanje ili sprječavanje bolesti ili poremećaja, pri čemu bolest ili poremećaj je rak, poremećaj povezan s angiogenezom, bol, makularna degeneracija ili srodni sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitska bolest, poremećaj imunodeficijencije, poremećaj središnjeg živčanog sustava, ozljeda središnjeg živčanog sustava, ateroskleroza ili srodni poremećaj, disfunkcionalni san ili srodni poremećaj, zarazna bolest, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s TNFa.
causing an intervention to be output that has a different amount of biological or pharmaceutical substance than the intervention in the subset. A program storage device readable by a machine, tangibly embodying a program of instructions executable by the machine to perform method steps for increasing protein food safety, the method steps comprising: 
Uređaj za pohranu strojno čitljivog programa, koji opipljivo utjelovljuje programske upute koje može izvršiti stroj, kako bi se provelo korake postupka povećavanja sigurnosti proteinske hrane, naznačen time što se koraci postupka obuhvaćaju: prijem podataka o razini onečišćenja;
The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. 
Postupak iz patentnog zahtjeva 1, naznačen time, da je cjevovod prvog elektromagnetskog aplikatora postavljen horizontalno u odnosu na tlo.
The compound according to any one selected from claims 1 to 4, or a pharmacologically acceptable salt thereof, wherein R3 represents a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a 2,2,2-trifluoroethoxy group, a pyrrolidin-1-yl group, a piperidin-1-yl group, a diethylamino group, a cyclopropylmethoxy group, or a methoxy group. 
Spoj ili njegova farmakološki prihvatljiva sol, ili hidrat spoja ili njegova farmakološki prihvatljiva sol, u skladu sa bilo kojim odabranim patentnim zahtjevom 1 do 4, gdje R3 predstavlja atom vodika, atom fluora, atom klora, atom broma, trifluorometil grupu, 2,2,2-trifluoroetoksi grupu, pirolidin-1-il grupu, piperidin-1-il grupu, dietilamino grupu, ciklopropilmetoksi grupu, ili metoksi grupu.
optionally isolating the compound of formula I or a pharmaceutically acceptable salt thereof as obtained in step d). 
€) po izboru, izolacije spoja formule I ili njegove farmaceutski prihvatljive soli koji su dobiveni u koraku d).
the lysine at position 9 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, E, F, G, I, L, M, N, P, Q, R, S, T, V, W, and Y; 
lizin na položaju 9 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, L, M, N, P, Q, R, S, T, V, W te Y;
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
Ry je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heleroarilalkila, i (NRcRp)sulfonila; a Rc 1 Ry su neovisno odabrani iz skupine koja se sastoji od vodik 1 alkila.
The compound according to claim 1, wherein said compound has formula (VII): 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (VII):
a transceiver configured to transmit and receive a signal over a network; and a processor coupled with the transceiver and configured to control to: 
odašiljača konfiguriranog za prijenos kontrolnog signala uporabom frekvencijskog resursa; i upravljačkog uređaja konfiguriranog za:
The polypeptide according to any of the preceding claims, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 836, or 
Polipeptid prema zahtjevu 9, naznačen time da polipeptid sadrži ili se sastoji od aminokiselinske sekvence SEQ ID NO: 836. Polipeptid prema bilo kojem od zahtjeva 1-10, naznačen time da polipeptid sadrži
A process for the preparation of gabapentin which comprises: 
Postupak pripreme gabapentina koji obuhvaća: a.
Preferably, the retinal derivative is selected from the group consisting of 3,4-dehydroretinal, 13-ethylretinal, 9-dm-retinal, 3-hydroxyretinal, 4-hydroxyretinal, naphthylretinal; 3,7,11-trimethyl-dodeca-2,4,6,8,10-pentaenal; 3,7-dimethyl-deca-2,4,6,8-tetraenal; 3,7-dimethyl-octa-2,4,6-trienal; and 6-7 rotation-blocked retinals, 8-9 rotation-blocked retinals, and 10-11 rotation-blocked retinals. 
Kanalski rodopsin, obuhvaća ionski kanal induciran svjetlom u skladu s patentnim zahtjevima 1-6 i retinal ili derivat retinala, pri čemu je poželjno derivat retinala odabran iz grupe koja se sastoji od 3,4-dehidroretinala, 13- etilretinala, 9-dm-retinala, 3-hidroksiretinala, 4-hidroksiretinala, naftilretinala; 3,7,11-trimetil-dodeka-2,4,6,8,10- pentaenala; 3,7-dimetil-deka-2,4,6,8-tertaenala; 3,7-dimetil-okta-2,4,6-trienala 1 6-7 rotacijski blokiranih retinala, 89 rotacijski blokiranih retinala i 10-11 rotacijski blokiranih retinala.
A host cell comprising the nucleic acid or the expression vector according to claim 5, wherein said host cell preferably is an antigen presenting cell, for example a dendritic cell, and wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline u skladu s patentnim zahtjevom 5 ili vektor ekspresije u skladu s patentnim zahtjevom 6, pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
In cats, oral administration of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride caused a dose-dependent increase in awakening at the expense of SWS, in particular SW2, and of PS. 
Kod mačaka, oralna je primjena 1-[3-[3-(4-klorfenil)propoksilpropill-piperidin monoklorida dovela do o dozi ovisnom povećanju buđenja na štetu SWS-a, posebice SW2 i PS.
The oral solid pharmaceutical composition according to any of the preceding claims, wherein the amount of particles of a Lenalidomide modification is in the range of from 2.0% to 20.0% by weight, more preferably from 3.0% to 10.0% by weight and most preferred from 4.0% to 8.0% by weight. 
Oralni kruti farmaceutski sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da količina čestica modifikacije Lenalidomida jest u području od 2,0 tež% do 20,0 tež%, pogodnije od 3,0 tež% do 10,0 tež% i najpogodnije od 4,0 tež% do 8,0 tež%.
The compound of Claim 15, where R3, R4, and R5 are hydrogen, and: 
Spoj u skladu s patentnim zahtjevom 15, naznačen time, da su R3, R4, i R5 vodik, a:
• heating the décor (8) and the paper (2) with the resin, preferably by using an IR lamp (7); and 
* zagrijavanja dekora (8) i papira (2) sa smolom, poželjno upotrebom IC lampe (7); 1
providing a water solution of quillaja saponin micelles; and adding the water solution comprising the saponin micelles to the sterol membrane, whereby a complex is formed between the saponins and the sterols and is suspended in the water solution. 
dodavanja vodene otopine koja sadrži micele saponina u sterolsku membranu, pri čemu se formira kompleks između saponina i sterola koji se suspendira u vodenoj otopini, i naznačeno time da je odnos kolesterola i kvilaja saponina od 1:10 do 10:1, poželjno od 1:2 od 2:1.
A pharmaceutical composition comprising any one of the compounds of claim 6 or a salt thereof, together with a pharmaceutically acceptable carrier, said carrier including an additive selected from the group consisting of adjuvants, excipients, diluents, and stablilizers. 
Farmaceutska kompozicija koja sadrži spoj iz patentnog zahtjeva 14 ili sol istog, zajedno sa farmaceutski prihvatljivim nosačem, pri čemu navedeni nosač uključuje dodatak odabran iz grupe koja se sastoji od pomoćnih sredstava, ekscipijenasa, razrjeđivača i stabilizatora.
Preferred Embodiments A method for producing a recombinant Von Willebrand Factor (rVWF) composition, the method comprising the steps of: 
Postupak dobivanja pripravka rekombinantnog Von Willebrandovog Čimbenika (rVWF), naznačen time što se postupak sastoji u koracima:
is selected from a methyl or cyclopropyl group, R2 represents a hydrogen atom, R3 is a COOH group, R4 represents a hydrogen atom, G1 is selected from nitrogen atoms and CH, C(CH3) and C(CF3) groups and G2 represents a phenyl group optionally substituted with one or two substituents selected from chloro, fluoro, methoxy, ethoxy, isopropoxy, trifluoromethoxy and -CONR7R8, wherein R7 is hydrogen and R8 is cyclopropyl or R7 and R8 together with the nitrogen atom to which they are attached form a group of formula wherein n is 1. 
odabran je iz metilne ili ciklopropilne skupine, R2 predstavlja atom vodika, R3 je COOH skupina, R4 predstavlja atom vodika, G1 odabran je iz atoma dušika i CH, C(CH3) i C(CF3) skupina i G2 predstavlja fenilnu skupinu po izboru supstituiranu s jednim ili s dva supstituenta koji su odabran između kloro, fluoro, metoksi, etoksi, isopropoksi, trifluorometoksi i -CONR7R8, pri čemu je R7 vodik, a R8 je ciklopropil ili R7 i R8 zajedno s atomom dušika na koji su vezani čine skupinu formule [image] u kojoj je n 1.
The system of claim 1 wherein the pressurized air source comprises a compressor producing pressurized air output on the order of 5 to 100 psi. 
Sustav prema zahtjevu 1, naznačen time što izvor zraka pod tlakom obuhvaća jedan kompresor koji na izlazu proizvodi zrak pod tlakom reda veličine 1 do 100 psi.
is any amino acid residue, n and m, independently, are 0 or an integer of more than 0, and wherein the amino acid sequence according to Formula I is not identical with, or does not comprise the 7-mer polypeptide fragment of alpha-synuclein having the amino acid sequence KNEEGAP, said at least one peptide or polypeptide having a binding capacity to an antibody which is specific for an epitope of alpha-synuclein comprising the amino acid sequence KNEEGAP for use in preventing and/or treating synucleinopathies. 
X; je bilo koji aminokiselinski ostatak, nim su međusobno neovisno 0 ili neki cijeli broj veći od 0, i čime aminokiselinska sekvenca prema formuli I nije identična sa sedmomernim fragmentom polipeptida od alfa- sinukleina koji ima aminokiselinsku sekvencu KNEEGAP, ili ga ne sadrži, gdje navedeni najmanje jedan peptid ili polipeptid ima kapacitet za vezanje na protutijelo specifično za epitop od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP, te time, da je za uporabu u prevenciji i/ili liječenju sinukleinopatija.
Preferably the interchain cysteine of CL is at position 214 of the light chain and the interchain cysteine of CH1 is at position 233 of the heavy chain (Kabat et al. (supra)). 
Antitijelo prema zahtjevu 6 naznačeno time da je međulančani cistein iz Cr na položaju 214 u lakom lancu (prema Kabat-numeriranju) i međulančani cistein iz Cgl je na položaju 233 u teškom lancu (prema Kabat-numeriranju).
The present invention also provides an isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody molecule of the present invention. 
Izolirana DNK sekvenca koja kodira teški i laki lanac(e) antitijela prema zahtjevu 1 ili prema zahtjevu 2.
A glassy lozenge according to claim 1 wherein the anti-emetic agent is ondansetron. 
Tableta-pastila prema patentnom zahtjevu 31, naznačena time što je anti-emetičko sredstvo ondansetron.
A pharmaceutical composition comprising (a) a cyclopolysaccharide, and (b) a compound of Formula (I) 
PATENTNI ZAHTJEVI Farmaceutski sastav sadržeći (a) ciklični polisaharid, te (b) spoj Formule (II):
a disease relapse, optionally wherein said disease relapse occurs after treatment with an E . coli L-asparaginase or PEGylated form thereof. 
(b) povrat bolesti, proizvoljno pri čemu se navedeni povrat bolesti javlja nakon liječenja s L-asparaginazom £.coli ili njezinim PEG-iliranim oblikom.
a fluid inlet (16) being in contact with said fluid channel (23), and 
- - ulazni otvor (16) koji je u kontaktu s navedenim kanalom za fluid (23), 1
recovering at least a portion of the culture supernatant, wherein the cell density is maintained at less than 4.0x106 cells per mL during the step of culturing the one or more mammalian cells; and wherein at least 1500 Units FRETS-VWF73 activity per liter supplemented basal cell culture media per day is present in the recovered culture supernatant. 
uzgoja jedne ili više stanica u mediju za kulturu stanica nadopunjenom bakrom, tako da se rA13 eksprimira i izlučuje iz stanica u supernatant kulture, gdje se sadržaj NH4+ u supernatantu kulture stanica održava u koncentraciju od najviše 5 mM; i prikupljanja u najmanju ruku dijela supernatanta kulture, gdje je u prikupljenom supernatantu kulture prisutna aktivnost od najmanje 1500 jedinica FRETS-VWF73 po litri nadopunjenog medija za osnovnu kulturu stanica dnevno.
The compound of claim 2, wherein Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus is a free terminus. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što Aaa je aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je C-kraj slobodni kraj.
A method of treating inflammatory bowel disease in a human, the method comprising administering to the human a pharmaceutical composition comprising a therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (“Compound A”) or its pharmaceutically acceptable salt, 
[(2-Hidroksi-4-okso-6,7,8,9-tetrahidro-4H,5H-10-tia-1,4a-diaza-benzo[a]azulen-3-karbonil)-amino]-sirćetna kiselina ili njena farmaceutski prihvatljiva sol, za upotrebu u liječenju inflamatorne crijevne bolesti, u doznom opsegu od 2,5 mg do 60 mg.
A compound of any one of claims 1-9, wherein the compound has hMGAT2 IC50 values ≤ 1 µM, using the MGAT2 LCMS assay. 
Spoj iz bilo kojeg od patentnih zahtjeva 1-9, gdje spoj ima hMGAT2 IC50 vrijednosti ≤ 1 µM, korištenjem MGAT2 LCMS testa.
loading (402) a bar stock of material into a screw cutting machine; cutting (410) a thread into at least a portion of the bar stock with a rotating cutting head; and forming (410) a plurality of facets in said thread during said cutting by imparting a controlled vibratory effect on the bar stock during said cutting, said imparting of a controlled vibratory effect allows the bar stock to vibrate during said cutting and comprises selecting a guide bushing for the screw cutting machine having a predetermined clearance with respect to the bar stock, said clearance providing a desired harmonic level for allowing the bar stock to vibrate within the same and thereby generating the controlled vibratory effect of the bar stock; 
Postupak proizvodnje ortopedskog vijka koji obuhvaća: punjenje (402) uređaja za rezanje vijaka materijalom; rezanje (410) niti u barem dio materijala pomoću rotirajuće glave za rezanje; i formiranje (410) više faseta u niti tijekom rezanja djelovanjem kontroliranim vibracijskim učinkom na materijal tijekom rezanja, djelovanje kontroliranim vibracijskim učinkom omogućava da materijal vibrira tijekom rezanja 1 obuhvaća odabir vodeće čahure za stroj za rezanje vijaka s prethodno određenom prazninom koja omogućava harmoničnu razinu za omogućavanje vibracija materijala unutar istog i generiranje kontroliranog vibratornog učinka materijala; faseti su formirani pomoću više vrhova i udubina različite dubine koji se pružaju transverzalno prema i unutar niti u barem dijelu istoga.
the plurality of bonded portions comprises first and second pluralities of the bonded portions; 
mnoštvo spojenih dijelova sadrži prvo i drugo mnoštvo spojenih dijelova;
According to a further embodiment of the invention, the step-shaped cross-section on the side of the intermediate plate facing the punch plate has a first inside dimension that corresponds to an outside dimension of the bolt. 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time što stupnjeviti poprečni presjek ima, na strani međuploče (ZW) okrenutoj prema ploča za žigosanje (ST), prvu unutarnju dimenziju (IA1), koja odgovara vanjskoj dimenziji svornjaka (BO).
Method to obtain 2-methylthioisosorbide 5-mononitrate (3) 
Postupak za dobivanje 2-metiltioizosorbid 5-mononitrata (3).
The compound of Paragraph 25, wherein R41 is selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu je R4, izabran iz skupine koju čine -H, metil, etil, propil, izopropil, ciklopropil, metoksi, etoksi, propoksi 1 ciklopropoksi.
A compound of Claim 19, wherein R3 is selected from the group consisting of hydrogen, 
Spoj prema Zahtjevu 19, naznačen time, da R; je odabran iz skupine koja sadrži
more than one copy of said nucleic acid is integrated into the host cell genome, optionally wherein 2-5 copies, 2 copies or 3 copies of the nucleic acid are integrated into the host cell genome; or 
(ii) više od jedne kopije spomenute nukleinske kiseline je integrirano u genom stanice domaćina, pri čemu opcionalno su 2-5 kopija, 2 kopije ili 3 kopije nukleinske kiseline integrirane u genom stanice domaćina; ili
System according to any one of the preceding claims comprising means for programming different operating cycles through the choice of the number or movements of sprays and washing water pressure and drying and ironing times of the hung and stretched garments on hangers or models (18) . 
Sustav u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ima sredstvo za programiranje različitih radnih ciklusa kroz odabir broja ili pokreta prskanja i tlaka vode za pranje, te trajanja sušenja 1 glačanja odjeće izvješene i ispružene na vješalicama ili modelima (18).
In an embodiment of the process, the organic solvent and the second organic solvent are the same. In another embodiment, the organic solvent and the second organic solvent are alcohols. 
Postupak prema patentnom zahtjevu 8, naznačen time, da su organsko otapalo i drugo organsko otapalo isti i oba su alkoholi, ili pri čemu su organsko otapalo i drugo organsko otapalo izopropanol.
The method according to claim 9, wherein said antigen-presenting cell comprises an expression vector expressing said peptide according to claim 1 or 2. 
Metoda u skladu s patentnim zahtjevom 9, pri čemu stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
Example 8.1: Prediction of the Ms-genotype 
Datum objave europske prijave patenta:
iv-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 257 ng/ml +/- 59 ng/ml following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions (day 1 of the above described study), and/or 
Vildagliptina od 257 ng/mL +/- 59 ng/mL nakon oralne primjene navedenog dozirnog oblika pacijentu koji nije bio tretiran vildagliptinom prije navedene primjene i pri čemu je pacijent pod uvjetima posta, i/ili kruti oralni dozirni oblik koji sadrži oko 150 mg vildagliptin slobodne baze ili odgovarajuću količinu njegove farmaceutski prihvatljive soli, te podlogu, pri čemu navedeni dozirni oblik pruža srednju vrijednost Cmax.
In another embodiment, a pharmaceutical composition is provided that comprises Compound I and one or more antidiabetic or incretin compounds other than Compound I in a single dose form. 
Farmaceutska kompozicija formulirana u pojedinačnom doznom obliku, pri čemu takav pojedinačni dozni oblik sadrži između 1 mg i 250 mg spoja I, pri čemu spoj I ima formulu
After another hour, HPLC indicated that the reaction was complete. The reaction mixture was filtered through celite and washed through with IPAc. 
Nakon sljedeća 24 sata, HPLC je pokazao da je reakcija bila dovršena, Reakcijska smjesa je bila filtrirana kroz celit i potpuno isprana s IPAc.
The method according to claim 9 wherein the amount of water added in step (i) is restricted to that amount necessary to ensure that the salt is formed. 
Postupak prema zahtjevu 9 gdje je količina vode koja se dodaje u koraku (1) ograničena na količinu koja je potrebna da se osigura formiranje soli.
Tumour volume was assessed twice weekly by bilateral Vernier calliper measurement, using the formula (length×width)×√(length×width)×(π/6), where length was the longest diameter across the tumour, and width was the corresponding perpendicular. 
Četrnaeast dana nakon implantacije, volumen tumora računat je dva puta tjedno pomoću pomične mjerke Vernier, i formule (duljina x širina) x v (duljna x širina) x (2/6), pri čemu je za duljinu uzet najveći promjer tumora, a širina je bila odgovarajuća duljina okomice.
(wherein R4 represents: 
(u kojoj R* predstavlja:
Compounds of the General Formula (I) and General Formula (II) of the present invention can be prepared according to the general sequence of reactions outlined below. 
Spoj Opće formule (II) prema zahtjevu 4, naznačen time, da je njegova uporaba u prevenciji ili liječenju poremećaja povezanih s aktiviranim sustavom imuniteta.
does not need a manual intervention, being totally automatic; 
- < nezahtijeva ručnu intervenciju, odnosno potpuno je automatiziran
The sulphonyl chlorides that are used to prepare these Examples are either commercially available or are prepared by methods described herein. 
Sulfonil kloridi koji su upotrijebljeni za pripravu ovih primjera su dostupni komercijalno ili su proizvedeni ovdje opisanim postupcima.
the base is subjected to catalytic hydrogenation with Pd-C catalyst in an ethanol or methanol solvent at the pressure of 1-15 bar at temperature of 25-100°C, then the Ivabradine hydrobromide salt of formula (I) is isolated, wherein the crystallization Ivabradine hydrobromide is carried out by cooling the methanol or ethanol solution. 
baza je podvrgnuta katakitičkom hidrogeniranju s Pd-C katalizatorom u etanolu ili metanolu kao otapalu pri tlaku 1-15 bara pri temperaturi 25-100°C, te se izolira sol Ivabradin hidrobromid formule (I), pri čemu se kristalizacija ivabradin hidrobromida provodi hlađenjem metanolne ili etanolne otopine.
In the embodiments described, the heat from the thermal treatment of the poultry litter is harnessed and used to heat the poultry sheds. 
što korak termičke obrade otpada od peradi obuhvaća spaljivanje otpada od peradi u jedinici s fluidiziranim slojem.
The method of claim 17, wherein the therapeutically effective amount of crenolanib or a salt thereof is provided in an amount that decreases patient circulating peripheral blood blast count. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina pripravka osigurana u količini koja smanjuje broj blasta u perifernom krvnom optoku.
fusion inhibitor Trizivir ® HIV infection, 
HIV infekcija, SIDA, inhibitor virusne fuzije